文献速递复苏、休克与脓毒症心脑血管急症

非ST段抬高室颤性院外心脏骤停后加速转运至心脏骤停中心的随机试验:ARREST先导随机试验

A Randomised tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation ventricular fibrillation out-of-hospital cardiac arrest: The ARREST pilot randomised trial.
PubMed 文献 · Resuscitation · 2017-02-04
一句话结论ARREST先导试验显示,院外心脏骤停后加速转运至心脏骤停中心的大规模随机对照试验在随机化、方案依从性和数据收集方面可行,但先导试验未显示30天死亡率等结局差异。

该先导随机试验纳入成人目击性室颤性院外心脏骤停且推测心源性病因者,1:1随机分为加速转运至心脏骤停中心接受目标导向治疗(包括即刻再灌注)组与转运至最近医院的标准治疗组。2014年11月至2016年4月筛查118例,63例(53%)符合标准,40例(63%)被随机化;治疗组无方案偏离,主要和次要结局数据收集完成83%。30天死亡率干预组9/18(50%)vs 对照组6/15(40%)(P=0.73),CPC 1/2干预组9/18(50%)vs 对照组7/14(50%)(P>0.99),MACCE干预组9/18(50%)vs 对照组6/15(40%)(P=0.73)。作者认为这些发现支持开展大规模随机对照试验的可行性和可接受性。

要点

  • 筛查118例目击性室颤性院外心脏骤停,63例(53%)符合标准,其中40例(63%)被随机化。
  • 治疗组无方案偏离,主要和次要结局数据收集完成83%。
  • 30天死亡率干预组9/18(50%)vs 对照组6/15(40%),P=0.73,无显著差异。
  • CPC 1/2干预组9/18(50%)vs 对照组7/14(50%),P>0.99,无显著差异。
  • MACCE干预组9/18(50%)vs 对照组6/15(40%),P=0.73,无显著差异。

适用人群与场景

  • 成人目击性室颤性院外心脏骤停,推测心源性病因,且无ST段抬高。

处置流程与药物剂量

  • 治疗组:加速转运至心脏骤停中心接受目标导向治疗,包括即刻再灌注。
  • 对照组:按现行标准治疗转运至地理上最近的医院。

研究设计与关键结果

  • 研究类型:先导随机对照试验;2014年11月至2016年4月筛查118例,63例(53%)符合标准,40例(63%)被随机化。
  • 主要终点30天全因死亡率:干预组9/18(50%)vs 对照组6/15(40%),P=0.73,无显著差异。
  • 次要终点CPC 1/2:干预组9/18(50%)vs 对照组7/14(50%),P>0.99,无显著差异。
  • 次要终点院内MACCE:干预组9/18(50%)vs 对照组6/15(40%),P=0.73,无显著差异。
  • 治疗组无方案偏离,主要和次要结局数据收集完成83%。

证据类型、等级与局限

  • 证据类型:先导随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些发现支持开展大规模随机对照试验的可行性和可接受性,以解决心脏骤停后治疗中尚存的不确定性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Wide variation exists in inter-hospital survival from out-of-hospital cardiac arrest (OHCA). Regionalisation of care into cardiac arrest centres (CAC) may improve this. We report a pilot randomised trial of expedited transfer to a CAC following OHCA without ST-elevation. The objective was to assess the feasibility of performing a large-scale randomised controlled trial.

METHODS: Adult witnessed ventricular fibrillation OHCA of presumed cardiac cause were randomised 1:1 to either: (1) treatment: comprising expedited transfer to a CAC for goal-directed therapy including access to immediate reperfusion, or (2) control: comprising current standard of care involving delivery to the geographically closest hospital. The feasibility of randomisation, protocol adherence and data collection of the primary (30-day all-cause mortality) and secondary (cerebral performance category (CPC)) and in-hospital major cardiovascular and cerebrovascular events (MACCE) clinical outcome measures were assessed.

RESULTS: Between November 2014 and April 2016, 118 cases were screened, of which 63 patients (53%) met eligibility criteria and 40 of the 63 patients (63%) were randomised. There were no protocol deviations in the treatment arm. Data collection of primary and secondary outcomes was achieved in 83%. There was no difference in baseline characteristics between the groups: 30-day mortality (Intervention 9/18, 50% vs. Control 6/15, 40%; P=0.73), CPC 1/2 (Intervention: 9/18, 50% vs. Control 7/14, 50%; P>0.99) or MACCE (Intervention: 9/18, 50% vs. Control 6/15, 40%; P=0.73).

CONCLUSIONS: These findings support the feasibility and acceptability of conducting a large-scale randomised controlled trial of expedited transfer to CAC following OHCA to address a remaining uncertainty in post-arrest care.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Patterson T, Perkins GD, Joseph J, et al. A Randomised tRial of Expedited transfer to a cardiac arrest centre for non-ST elevation ventricular fibrillation out-of-hospital cardiac arrest: The ARREST pilot randomised trial. Resuscitation. 2017. PMID: 28174052. doi:10.1016/j.resuscitation.2017.01.020

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。